{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T22:08:58Z","timestamp":1791842938536,"version":"4.3.4"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T00:00:00Z","timestamp":1776470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"vor","delay-in-days":11,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"DOI":"10.1186\/s12886-026-04816-7","type":"journal-article","created":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T07:04:47Z","timestamp":1776495887000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of low-concentration atropine combined with orthokeratology for children with myopia: a systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1186","volume":"26","author":[{"given":"Xue-Qian","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Nan","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le-Huan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-Yu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Xue","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,18]]},"reference":[{"issue":"5","key":"4816_CR1","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1136\/bjo-2024-326643","volume":"109","author":"LS Eppenberger","year":"2025","unstructured":"Eppenberger LS, Davis A, Resnikoff S, Wong TY, Lan W, Saw SM, He MG, Ohno-Matsui K, Jonas JB, Qu J, et al. Key strategies to reduce the global burden of myopia: consensus from the international myopia summit. Br J Ophthalmol. 2025;109(5):535\u201342.","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"4816_CR2","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1136\/bjo-2024-325427","volume":"109","author":"J Liang","year":"2025","unstructured":"Liang J, Pu Y, Chen J, Liu M, Ouyang B, Jin Z, Ge W, Wu Z, Yang X, Qin C, et al. Global prevalence, trend and projection of myopia in children and adolescents from 1990 to 2050: a comprehensive systematic review and meta-analysis. Br J Ophthalmol. 2025;109(3):362\u201371.","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"4816_CR3","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S1350-9462(02)00063-0","volume":"22","author":"NA McBrien","year":"2003","unstructured":"McBrien NA, Gentle A. Role of the sclera in the development and pathological complications of myopia. Prog Retin Eye Res. 2003;22(3):307\u201338.","journal-title":"Prog Retin Eye Res"},{"key":"4816_CR4","doi-asserted-by":"crossref","unstructured":"Suda K, Miyake M, Akagi T, Ikeda HO, Kameda T, Hasegawa T, Numa S, Tsujikawa A. Exploration of the cutoff values of axial length that is susceptible to develop advanced primary open angle glaucoma in patients aged less than 50 years. Graefes Arch Clin Exp Ophthalmol. 2025.","DOI":"10.1007\/s00417-025-06827-4"},{"issue":"10","key":"4816_CR5","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1001\/jamaophthalmol.2021.3303","volume":"139","author":"R Du","year":"2021","unstructured":"Du R, Xie S, Igarashi-Yokoi T, Watanabe T, Uramoto K, Takahashi H, Nakao N, Yoshida T, Fang Y, Ohno-Matsui K. Continued Increase of Axial Length and Its Risk Factors in Adults With High Myopia. JAMA Ophthalmol. 2021;139(10):1096\u2013103.","journal-title":"JAMA Ophthalmol"},{"issue":"4","key":"4816_CR6","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.ophtha.2015.11.010","volume":"123","author":"J Huang","year":"2016","unstructured":"Huang J, Wen D, Wang Q, McAlinden C, Flitcroft I, Chen H, Saw SM, Chen H, Bao F, Zhao Y, et al. Efficacy comparison of 16 interventions for myopia control in children: A network meta-analysis. Ophthalmology. 2016;123(4):697\u2013708.","journal-title":"Ophthalmology"},{"issue":"12","key":"4816_CR7","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1016\/j.ophtha.2006.05.062","volume":"113","author":"WH Chua","year":"2006","unstructured":"Chua WH, Balakrishnan V, Chan YH, Tong L, Ling Y, Quah BL, Tan D. Atropine for the treatment of childhood myopia. Ophthalmology. 2006;113(12):2285\u201391.","journal-title":"Ophthalmology"},{"issue":"2","key":"4816_CR8","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.ophtha.2011.07.031","volume":"119","author":"A Chia","year":"2012","unstructured":"Chia A, Chua WH, Cheung YB, Wong WL, Lingham A, Fong A, Tan D. Atropine for the treatment of childhood myopia: safety and efficacy of 0.5%, 0.1%, and 0.01% doses (Atropine for the Treatment of Myopia 2). Ophthalmology. 2012;119(2):347\u201354.","journal-title":"Ophthalmology"},{"issue":"3","key":"4816_CR9","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.ophtha.2021.10.016","volume":"129","author":"A Ha","year":"2022","unstructured":"Ha A, Kim SJ, Shim SR, Kim YK, Jung JH. Efficacy and Safety of 8 Atropine Concentrations for Myopia Control in Children: A Network Meta-Analysis. Ophthalmology. 2022;129(3):322\u201333.","journal-title":"Ophthalmology"},{"issue":"7","key":"4816_CR10","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.ophtha.2023.02.020","volume":"130","author":"MA Bullimore","year":"2023","unstructured":"Bullimore MA, Brennan NA. Efficacy in Myopia Control: The Low-Concentration Atropine for Myopia Progression (LAMP) Study. Ophthalmology. 2023;130(7):771\u20132.","journal-title":"Ophthalmology"},{"issue":"9","key":"4816_CR11","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.ophtha.2024.03.013","volume":"131","author":"XJ Zhang","year":"2024","unstructured":"Zhang XJ, Zhang Y, Yip BHK, Kam KW, Tang F, Ling X, Ng MPH, Young AL, Wu PC, Tham CC, et al. Five-Year Clinical Trial of the Low-Concentration Atropine for Myopia Progression (LAMP) Study: Phase 4 Report. Ophthalmology. 2024;131(9):1011\u201320.","journal-title":"Ophthalmology"},{"issue":"11","key":"4816_CR12","doi-asserted-by":"publisher","first-page":"7077","DOI":"10.1167\/iovs.12-10565","volume":"53","author":"P Cho","year":"2012","unstructured":"Cho P, Cheung SW. Retardation of myopia in Orthokeratology (ROMIO) study: a 2-year randomized clinical trial. Invest Ophthalmol Vis Sci. 2012;53(11):7077\u201385.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"4","key":"4816_CR13","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1097\/ICL.0000000000000520","volume":"44","author":"MJ Lipson","year":"2018","unstructured":"Lipson MJ, Brooks MM, Koffler BH. The Role of Orthokeratology in Myopia Control: A Review. Eye Contact Lens. 2018;44(4):224\u201330.","journal-title":"Eye Contact Lens"},{"issue":"5","key":"4816_CR14","doi-asserted-by":"publisher","first-page":"e0323546","DOI":"10.1371\/journal.pone.0323546","volume":"20","author":"ZY Meng","year":"2025","unstructured":"Meng ZY, Yang L, Zhou P. Analysis of axial shortening induced by orthokeratology lenses and its mechanical mechanisms. PLoS ONE. 2025;20(5):e0323546.","journal-title":"PLoS ONE"},{"issue":"4","key":"4816_CR15","doi-asserted-by":"publisher","first-page":"101371","DOI":"10.1016\/j.clae.2020.10.001","volume":"44","author":"A S\u00e1nchez-Garc\u00eda","year":"2021","unstructured":"S\u00e1nchez-Garc\u00eda A, Ariza MA, B\u00fcchler P, Molina-Martin A, Pi\u00f1ero DP. Structural changes associated to orthokeratology: A systematic review. Cont Lens Anterior Eye. 2021;44(4):101371.","journal-title":"Cont Lens Anterior Eye"},{"issue":"4","key":"4816_CR16","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1111\/cxo.12839","volume":"102","author":"P Cho","year":"2019","unstructured":"Cho P, Tan Q. Myopia and orthokeratology for myopia control. Clin Exp Optom. 2019;102(4):364\u201377.","journal-title":"Clin Exp Optom"},{"issue":"4","key":"4816_CR17","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.ophtha.2018.11.026","volume":"126","author":"DK VanderVeen","year":"2019","unstructured":"VanderVeen DK, Kraker RT, Pineles SL, Hutchinson AK, Wilson LB, Galvin JA, Lambert SR. Use of Orthokeratology for the Prevention of Myopic Progression in Children: A Report by the American Academy of Ophthalmology. Ophthalmology. 2019;126(4):623\u201336.","journal-title":"Ophthalmology"},{"issue":"1","key":"4816_CR18","doi-asserted-by":"publisher","first-page":"102282","DOI":"10.1016\/j.clae.2024.102282","volume":"48","author":"L Wen","year":"2025","unstructured":"Wen L, Liu H, Xu Q, Pan W, Lin Z, Xiao Z, Yang Z, Lan W, Chen Z. Add-on effect of using 0.05% atropine in fast progressors of orthokeratology: A preliminary retrospective study. Cont Lens Anterior Eye. 2025;48(1):102282.","journal-title":"Cont Lens Anterior Eye"},{"issue":"24","key":"4816_CR19","doi-asserted-by":"publisher","first-page":"e38384","DOI":"10.1097\/MD.0000000000038384","volume":"103","author":"Y Guo","year":"2024","unstructured":"Guo Y, Liu Y, Hu Z, Li Y, Zhang H, Zhao S. Efficacy and safety of 0.01% atropine combined with orthokeratology lens in delaying juvenile myopia: An observational study. Med (Baltim). 2024;103(24):e38384.","journal-title":"Med (Baltim)"},{"issue":"10","key":"4816_CR20","first-page":"Ed000142","volume":"10","author":"M Cumpston","year":"2019","unstructured":"Cumpston M, Li T, Page MJ, Chandler J, Welch VA, Higgins JP, Thomas J. Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Database Syst Rev. 2019;10(10):Ed000142.","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"4816_CR21","doi-asserted-by":"publisher","first-page":"M20","DOI":"10.1167\/iovs.18-25957","volume":"60","author":"DI Flitcroft","year":"2019","unstructured":"Flitcroft DI, He M, Jonas JB, Jong M, Naidoo K, Ohno-Matsui K, Rahi J, Resnikoff S, Vitale S, Yannuzzi L. IMI - Defining and Classifying Myopia: A Proposed Set of Standards for Clinical and Epidemiologic Studies. Invest Ophthalmol Vis Sci. 2019;60(3):M20\u201330.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"4816_CR22","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng HY, Corbett MS, Eldridge SM, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.","journal-title":"BMJ"},{"key":"4816_CR23","unstructured":"\u82cf\u65e5\u5a1c. \u89d2\u819c\u5851\u5f62\u955c\u8054\u54080.01%\u963f\u6258\u54c1\u6ef4\u773c\u6db2\u5bf9\u9752\u5c11\u5e74\u8fd1\u89c6\u7684\u9632\u63a7\u7814\u7a76. \u7855\u58eb. 2024."},{"key":"4816_CR24","unstructured":"\u9ad8\u5b88\u94ed. \u9a6c\u59dd\u5a77, \u674e\u4e3d\u971e, \u6bdb\u5ef6\u7130: \u89d2\u819c\u5851\u5f62\u955c\u548c\u4f4e\u6d53\u5ea6\u963f\u6258\u54c1\u5728\u513f\u7ae5\u8fd1\u89c6\u63a7\u5236\u4e2d\u7684\u4f5c\u7528. \u4e2d\u56fd\u73b0\u4ee3\u533b\u751f. 2021;59(12)."},{"key":"4816_CR25","unstructured":"\u5218\u7d20\u9e3d. \u5f20\u8273, \u66f9\u840c\u840c: \u89d2\u819c\u5851\u5f62\u955c\u8054\u54080.01%\u4f4e\u6d53\u5ea6\u963f\u6258\u54c1\u6cbb\u7597\u513f\u7ae5\u8fd1\u89c6\u4e34\u5e8a\u7597\u6548\u53ca\u5bf9\u773c\u751f\u7269\u5b66\u53c2\u6570\u7684\u5f71\u54cd. \u5b9e\u7528\u9632\u76f2\u6280\u672f. 2023;18(3)."},{"key":"4816_CR26","unstructured":"\u6731\u6885\u7ea2 \u6797\u6cf0\u5357. 0.01%\u4f4e\u6d53\u5ea6\u963f\u6258\u54c1\u6ef4\u773c\u6db2\u8054\u5408\u89d2\u819c\u5851\u5f62\u955c\u5bf9\u9752\u5c11\u5e74\u4e2d\u4f4e\u5ea6\u8fd1\u89c6\u63a7\u5236\u7684\u6548\u679c. \u4e2d\u5916\u533b\u5b66\u7814\u7a76. 2022;20(29)."},{"issue":"9","key":"4816_CR27","doi-asserted-by":"publisher","first-page":"2963","DOI":"10.1007\/s10792-021-01855-5","volume":"41","author":"Q Hao","year":"2021","unstructured":"Hao Q, Zhao Q. Changes in subfoveal choroidal thickness in myopic children with 0.01% atropine, orthokeratology, or their combination. Int Ophthalmol. 2021;41(9):2963\u201371.","journal-title":"Int Ophthalmol"},{"issue":"1","key":"4816_CR28","doi-asserted-by":"publisher","first-page":"12750","DOI":"10.1038\/s41598-020-69710-8","volume":"10","author":"N Kinoshita","year":"2020","unstructured":"Kinoshita N, Konno Y, Hamada N, Kanda Y, Shimmura-Tomita M, Kaburaki T, Kakehashi A. Efficacy of combined orthokeratology and 0.01% atropine solution for slowing axial elongation in children with myopia: a 2-year randomised trial. Sci Rep. 2020;10(1):12750.","journal-title":"Sci Rep"},{"issue":"5","key":"4816_CR29","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1007\/s10384-018-0608-3","volume":"62","author":"N Kinoshita","year":"2018","unstructured":"Kinoshita N, Konno Y, Hamada N, Kanda Y, Shimmura-Tomita M, Kakehashi A. Additive effects of orthokeratology and atropine 0.01% ophthalmic solution in slowing axial elongation in children with myopia: first year results. Jpn J Ophthalmol. 2018;62(5):544\u201353.","journal-title":"Jpn J Ophthalmol"},{"issue":"1","key":"4816_CR30","doi-asserted-by":"publisher","first-page":"101723","DOI":"10.1016\/j.clae.2022.101723","volume":"46","author":"Q Tan","year":"2023","unstructured":"Tan Q, Ng AL, Cheng GP, Woo VC, Cho P. Combined 0.01% atropine with orthokeratology in childhood myopia control (AOK) study: A 2-year randomized clinical trial. Cont Lens Anterior Eye. 2023;46(1):101723.","journal-title":"Cont Lens Anterior Eye"},{"issue":"5","key":"4816_CR31","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1111\/opo.12722","volume":"40","author":"Q Tan","year":"2020","unstructured":"Tan Q, Ng AL, Choy BN, Cheng GP, Woo VC, Cho P. One-year results of 0.01% atropine with orthokeratology (AOK) study: a randomised clinical trial. Ophthalmic Physiol Opt. 2020;40(5):557\u201366.","journal-title":"Ophthalmic Physiol Opt"},{"issue":"6","key":"4816_CR32","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1111\/opo.12730","volume":"40","author":"SJ Vincent","year":"2020","unstructured":"Vincent SJ, Tan Q, Ng ALK, Cheng GPM, Woo VCP, Cho P. Higher order aberrations and axial elongation in combined 0.01% atropine with orthokeratology for myopia control. Ophthalmic Physiol Opt. 2020;40(6):728\u201337.","journal-title":"Ophthalmic Physiol Opt"},{"issue":"6","key":"4816_CR33","first-page":"575","volume":"41","author":"L Liu","year":"2021","unstructured":"Liu L, Kuang G, Peng J. Effects of low-dose Atropine combined with orthokeratology on vision correction, tear film function and SF-36 score in adolescents with low to moderate myopia. Recent Adv Ophthalmol. 2021;41(6):575\u20138.","journal-title":"Recent Adv Ophthalmol"},{"issue":"3","key":"4816_CR34","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1111\/j.1444-0938.2006.00044.x","volume":"89","author":"HA Swarbrick","year":"2006","unstructured":"Swarbrick HA. Orthokeratology review and update. Clin Exp Optom. 2006;89(3):124\u201343.","journal-title":"Clin Exp Optom"},{"key":"4816_CR35","doi-asserted-by":"crossref","unstructured":"Lawrenson JG, Shah R, Huntjens B, Downie LE, Virgili G, Dhakal R, Verkicharla PK, Li D, Mavi S, Kernohan A, et al. Interventions for myopia control in children: a living systematic review and network meta-analysis. Cochrane Database Syst Reviews. 2023; 2023(2).","DOI":"10.1002\/14651858.CD014758.pub2"},{"issue":"22","key":"4816_CR36","doi-asserted-by":"publisher","first-page":"e29409","DOI":"10.1097\/MD.0000000000029409","volume":"101","author":"Y Gao","year":"2022","unstructured":"Gao Y, Yu Y. The effect of 0.01% atropine on ocular axial elongation for myopia children: A protocol for systematic review and meta-analysis. Med (Baltim). 2022;101(22):e29409.","journal-title":"Med (Baltim)"},{"issue":"1","key":"4816_CR37","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s10792-019-01167-9","volume":"40","author":"M Guan","year":"2020","unstructured":"Guan M, Zhao W, Geng Y, Zhang Y, Ma J, Chen Z, Peng M, Li Y. Changes in axial length after orthokeratology lens treatment for myopia: a meta-analysis. Int Ophthalmol. 2020;40(1):255\u201365.","journal-title":"Int Ophthalmol"},{"issue":"9","key":"4816_CR38","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1097\/OPX.0000000000000894","volume":"93","author":"Z Chen","year":"2016","unstructured":"Chen Z, Xue F, Zhou J, Qu X, Zhou X. Effects of Orthokeratology on Choroidal Thickness and Axial Length. Optom Vis Sci. 2016;93(9):1064\u201371.","journal-title":"Optom Vis Sci"},{"issue":"7","key":"4816_CR39","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1080\/02713683.2024.2310618","volume":"49","author":"J Xiao","year":"2024","unstructured":"Xiao J, Pan X, Hou C, Wang Q. Changes in Subfoveal Choroidal Thickness after Orthokeratology in Myopic Children: A Systematic Review and Meta-Analysis. Curr Eye Res. 2024;49(7):683\u201390.","journal-title":"Curr Eye Res"},{"issue":"1","key":"4816_CR40","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1097\/ICL.0000000000000189","volume":"42","author":"KC Shih","year":"2016","unstructured":"Shih KC, Chan TC, Ng AL, Lai JS, Li WW, Cheng AC, Fan DS. Use of Atropine for Prevention of Childhood Myopia Progression in Clinical Practice. Eye Contact Lens. 2016;42(1):16\u201323.","journal-title":"Eye Contact Lens"},{"issue":"2","key":"4816_CR41","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.ophtha.2015.07.004","volume":"123","author":"A Chia","year":"2016","unstructured":"Chia A, Lu QS, Tan D. Five-Year Clinical Trial on Atropine for the Treatment of Myopia 2: Myopia Control with Atropine 0.01% Eyedrops. Ophthalmology. 2016;123(2):391\u20139.","journal-title":"Ophthalmology"},{"issue":"12","key":"4816_CR42","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1016\/j.ophtha.2017.05.032","volume":"124","author":"SL Pineles","year":"2017","unstructured":"Pineles SL, Kraker RT, VanderVeen DK, Hutchinson AK, Galvin JA, Wilson LB, Lambert SR. Atropine for the Prevention of Myopia Progression in Children: A Report by the American Academy of Ophthalmology. Ophthalmology. 2017;124(12):1857\u201366.","journal-title":"Ophthalmology"},{"key":"4816_CR43","doi-asserted-by":"crossref","unstructured":"Chierigo A, Ferro Desideri L, Traverso CE, Vagge A. The role of atropine in preventing myopia progression: an update. Pharmaceutics. 2022;14(5).","DOI":"10.3390\/pharmaceutics14050900"},{"issue":"6","key":"4816_CR44","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1111\/j.1475-1313.2012.00940.x","volume":"32","author":"P Gallego","year":"2012","unstructured":"Gallego P, Mart\u00ednez-Garc\u00eda C, P\u00e9rez-Merino P, Ibares-Fr\u00edas L, Mayo-Iscar A, Merayo-Lloves J. Scleral changes induced by atropine in chicks as an experimental model of myopia. Ophthalmic Physiol Opt. 2012;32(6):478\u201384.","journal-title":"Ophthalmic Physiol Opt"},{"issue":"5","key":"4816_CR45","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1159\/000510779","volume":"64","author":"S Wang","year":"2021","unstructured":"Wang S, Wang J, Wang N. Combined Orthokeratology with Atropine for Children with Myopia: A Meta-Analysis. Ophthalmic Res. 2021;64(5):723\u201331.","journal-title":"Ophthalmic Res"},{"issue":"16","key":"4816_CR46","first-page":"3461","volume":"37","author":"G Zhang","year":"2023","unstructured":"Zhang G, Jiang J, Qu C. Myopia prevention and control in children: a systematic review and network meta-analysis. Eye (Basingstoke). 2023;37(16):3461\u20139.","journal-title":"Eye (Basingstoke)"},{"issue":"6","key":"4816_CR47","doi-asserted-by":"publisher","first-page":"2510","DOI":"10.1167\/iovs.06-0562","volume":"48","author":"DO Mutti","year":"2007","unstructured":"Mutti DO, Hayes JR, Mitchell GL, Jones LA, Moeschberger ML, Cotter SA, Kleinstein RN, Manny RE, Twelker JD, Zadnik K. Refractive error, axial length, and relative peripheral refractive error before and after the onset of myopia. Invest Ophthalmol Vis Sci. 2007;48(6):2510\u20139.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"4816_CR48","doi-asserted-by":"publisher","first-page":"38911","DOI":"10.1038\/s41598-025-22722-8","volume":"15","author":"Z Guo","year":"2025","unstructured":"Guo Z, Wei Z, Ming H, Zhang L, Ma B, Zhao Y, Guo L. Efficacy and safety of orthokeratology sequentially combined with escalating atropine concentrations for myopia control in children. Sci Rep. 2025;15(1):38911.","journal-title":"Sci Rep"},{"issue":"2","key":"4816_CR49","doi-asserted-by":"publisher","first-page":"210","DOI":"10.18502\/jovr.v15i2.6739","volume":"15","author":"K Singh","year":"2020","unstructured":"Singh K, Bhattacharyya M, Goel A, Arora R, Gotmare N, Aggarwal H. Orthokeratology in Moderate Myopia: A Study of Predictability and Safety. J Ophthalmic Vis Res. 2020;15(2):210\u20137.","journal-title":"J Ophthalmic Vis Res"},{"issue":"3","key":"4816_CR50","doi-asserted-by":"publisher","first-page":"e454","DOI":"10.1111\/aos.13866","volume":"97","author":"Z Li","year":"2019","unstructured":"Li Z, Hu Y, Cui D, Long W, He M, Yang X. Change in subfoveal choroidal thickness secondary to orthokeratology and its cessation: a predictor for the change in axial length. Acta Ophthalmol. 2019;97(3):e454\u20139.","journal-title":"Acta Ophthalmol"},{"issue":"6","key":"4816_CR51","first-page":"1259","volume":"41","author":"LF Hung","year":"2000","unstructured":"Hung LF, Wallman J, Smith EL. 3rd: Vision-dependent changes in the choroidal thickness of macaque monkeys. Invest Ophthalmol Vis Sci. 2000;41(6):1259\u201369.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"6","key":"4816_CR52","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1097\/APO.0000000000000232","volume":"5","author":"D Tan","year":"2016","unstructured":"Tan D, Tay SA, Loh KL, Chia A. Topical Atropine in the Control of Myopia. Asia Pac J Ophthalmol (Phila). 2016;5(6):424\u20138.","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"issue":"7","key":"4816_CR53","doi-asserted-by":"publisher","first-page":"e0282286","DOI":"10.1371\/journal.pone.0282286","volume":"18","author":"Z Wang","year":"2023","unstructured":"Wang Z, Wang P, Jiang B, Meng Y, Qie S, Yan Z. The efficacy and safety of 0.01% atropine alone or combined with orthokeratology for children with myopia: A meta-analysis. PLoS ONE. 2023;18(7):e0282286.","journal-title":"PLoS ONE"},{"issue":"3","key":"4816_CR54","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1111\/aos.16604","volume":"102","author":"R Iribarren","year":"2024","unstructured":"Iribarren R, Cunha C, Kaymak H, Grzybowski A. Preservatives and pH in low-dose atropine formulations for clinical trials. Acta Ophthalmol. 2024;102(3):364\u20136.","journal-title":"Acta Ophthalmol"},{"issue":"2","key":"4816_CR55","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/S0892-8967(98)00020-0","volume":"25","author":"J Mountford","year":"1998","unstructured":"Mountford J. Retention and regression of orthokeratology with time. Int Contact Lens Clin. 1998;25(2):59\u201364.","journal-title":"Int Contact Lens Clin"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12886-026-04816-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-026-04816-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-026-04816-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T14:03:15Z","timestamp":1777471395000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12886-026-04816-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,18]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4816"],"URL":"https:\/\/doi.org\/10.1186\/s12886-026-04816-7","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,18]]},"assertion":[{"value":"19 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"No generative artificial intelligence tools were employed in the preparation of this manuscript. All content was independently prepared by the author, who assumes sole responsibility for the authenticity and accuracy of its content.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"224"}}